- List
- By Topic
- On Map
- Search Details

"Hepatitis, Chronic"
Need help? See RSS Feeds
Choose a feed type:

"Hepatitis, Chronic" (1822 records)
Need help? See Downloading Content for Analysis
For Advanced Users: Full Study Record XML Download
1 | NCT02799355 | Completed | Treatment of Chronic Hepatitis With Sofosbuvir in Combination With Ribavirin With or Without Pegylated Interferon: North India Gastroenterology Consortium |
|
|
Observational |
|
Other |
|
|
1203 | All | 18 Years to 75 Years (Adult, Senior) | NCT02799355 | GCNI-CHC | GCNI-CHC | May 2016 | September 2016 | September 2016 | June 14, 2016 | September 27, 2016 |
|
||
2 | NCT01980290 | Completed | Telaprevir With Peginterferon Alfa & Ribavirin in Ex-People Who INject Drugs Infected by Genotype 1 Chronic Hepatitis C |
|
Observational |
|
Industry |
|
|
50 | All | 18 Years and older (Adult, Senior) | NCT01980290 | CR100966 VX-950HPC4017 |
INTEGRATE | May 2013 | February 2015 | February 2015 | November 8, 2013 | March 3, 2017 |
|
|||
3 | NCT01005238 | Terminated | Telbivudine Versus Lamivudine for Maintenance Therapy of Patients With Chronic Hepatitis B and Negative HBV Viral Load After 6 Month of Treatment With Telbivudine |
|
|
Interventional | Phase 4 |
|
Other |
|
|
27 | All | 18 Years and older (Adult, Senior) | NCT01005238 | SASL28 | SASL28 | September 2009 | December 2014 | October 30, 2009 | March 10, 2015 |
|
||
4 | NCT02893124 | Active, not recruiting | The Optimizing Treatment of Peginterferon (PEG IFN) Alpha in Chronic Hepatitis B Virus Patients With Low Level HBsAg |
|
|
Interventional | Phase 4 |
|
Other |
|
|
200 | All | 18 Years to 65 Years (Adult) | NCT02893124 | I-Cure-3 | August 2016 | August 2017 | September 8, 2016 | September 8, 2016 |
|
|||
5 | NCT02965859 | Recruiting | The Safety and Dose-range Study of Metacavir Enteric-coated Capsules in Patients With Chronic Hepatitis B |
|
|
Interventional | Phase 2 |
|
Industry |
|
|
180 | All | 18 Years to 65 Years (Adult) | NCT02965859 | PNA-20140110-v2 | December 2012 | December 2018 | November 17, 2016 | November 22, 2016 |
|
|||
6 | NCT02006823 | Completed | Patient Self-management and Gene Guided Therapy for Chronic Hepatitis C |
|
Observational |
|
Other |
|
|
20 | All | 18 Years and older (Adult, Senior) | NCT02006823 | Pro00035949 | March 2012 | July 2014 | July 2014 | December 10, 2013 | December 15, 2014 |
|
||||
7 | NCT02883647 | Recruiting | Therapeutic Effects and Long-term Follow-up After Ending Nucleos(t)Ide Analogs Therapy in Chronic Hepatitis b |
|
|
Observational |
|
Other |
|
|
100 | All | 18 Years to 65 Years (Adult) | NCT02883647 | PL | January 2014 | December 2017 | December 2017 | August 30, 2016 | August 30, 2016 |
|
|||
8 | NCT02364336 | Recruiting | Mechanisms Associated With Favorable Responses to Peginterferon-Alpha Add-on Therapy Following Long-term Nucleos(t)Ide Analogue Treatment in Patients With Chronic Hepatitis B |
|
|
Interventional | Phase 2 |
|
NIH |
|
|
60 | All | 18 Years to 80 Years (Adult, Senior) | NCT02364336 | 150082 15-DK-0082 |
February 14, 2015 | September 30, 2018 | September 30, 2018 | February 18, 2015 | March 29, 2018 |
|
||
9 | NCT01911156 | Unknown † | Sustained Off-treatment Response After HBeAg Loss in Chronic Hepatitis B Patients Treated With Nucleos(t)Ide Analogues |
|
|
Interventional | Phase 4 |
|
Other |
|
|
66 | All | 18 Years and older (Adult, Senior) | NCT01911156 | Stop Study GILEAD Sciences Canada, Inc. |
Stop | July 2013 | January 2016 | March 2016 | July 30, 2013 | May 28, 2015 |
|
|
10 | NCT02216045 | Completed | Effect of Camel Milk on Chronic Hepatitis C |
|
|
Interventional | Phase 2 |
|
Other |
|
|
40 | All | 18 Years to 70 Years (Adult, Senior) | NCT02216045 | Mashhad UMS | HCV | June 2014 | February 2015 | February 2015 | August 13, 2014 | July 29, 2016 |
|
|
11 | NCT02662712 | Recruiting | A Study of Orally Administered JNJ-56136379 to Evaluate Safety, Tolerability and Pharmacokinetics After Single Ascending Doses and One Multiple Dose Regimen in Healthy Participants (Part I), and After Multiple Dose Regimens in Participants With Chronic Hepatitis B (Part II) |
|
|
Interventional | Phase 1 |
|
Industry |
|
|
84 | All | 18 Years to 65 Years (Adult) | NCT02662712 | CR108092 56136379HPB1001 2015-003724-30 |
December 2015 | May 2018 | August 2018 | January 25, 2016 | March 29, 2018 |
|
||
12 | NCT00418639 | Completed | Study of Nitazoxanide in the Treatment of Chronic Hepatitis C |
|
|
Interventional | Phase 2 |
|
Industry |
|
|
50 | All | 18 Years and older (Adult, Senior) | NCT00418639 | RM01-3027 | February 2005 | January 5, 2007 | January 5, 2007 |
|
||||
13 | NCT00645736 | Completed | CHARM: Chronic Hepatitis B Antihepadnaviral Resistance Mutation Study |
|
|
Observational |
|
Industry |
|
|
788 | All | 18 Years and older (Adult, Senior) | NCT00645736 | GS-AU-103-0185 | CHARM | February 2008 | October 2008 | November 2008 | March 28, 2008 | November 22, 2011 |
|
||
14 | NCT01342185 | Unknown † | Efficacy of Medical Ozone Therapy in Patients With Chronic Hepatitis B |
|
|
Interventional | Phase 3 |
|
Other |
|
|
189 | All | 16 Years and older (Child, Adult, Senior) | NCT01342185 | a4xr2dv8 | EMOTCHB | March 2010 | July 2013 | July 2013 | April 27, 2011 | October 18, 2012 |
|
|
15 | NCT00828269 | Completed | Evaluation of RNA From the Liver Tissue Obtained in Patients With Chronic Hepatitis C (0000-123) |
|
|
Interventional | Phase 1 |
|
Industry |
|
|
12 | All | 18 Years to 65 Years (Adult) | NCT00828269 | 0000-123 123 2009_518 |
April 2009 | February 2010 | March 2010 | January 23, 2009 | April 22, 2015 | |||
16 | NCT01373684 | Recruiting | PEG-interferon Alfa-2a add-on Study in HBeAg Negative Chronic Hepatitis B Patients |
|
|
Interventional | Phase 4 |
|
Other / Industry |
|
|
90 | All | 18 Years and older (Adult, Senior) | NCT01373684 | HBV11-01 | PAS | March 2012 | June 2019 | October 2019 | June 15, 2011 | December 21, 2017 |
|
|
17 | NCT02058108 | Active, not recruiting | Study of Efficacy and Safety, Tolerability and Pharmacokinetics of Telbivudine in Children and Adolescents With Compensated Chronic Hepatitis B Virus Infection |
|
|
Interventional | Phase 3 |
|
Industry |
|
|
53 | All | 2 Years to 17 Years (Child) | NCT02058108 | CLDT600A2306 | October 31, 2014 | December 27, 2019 | December 27, 2019 | February 7, 2014 | August 3, 2017 |
|
||
18 | NCT00876174 | Terminated | Effects of Genotypes on Interferon Signaling in Chronic Hepatitis C |
|
|
Observational |
|
Other |
|
|
30 | All | 19 Years and older (Adult, Senior) | NCT00876174 | 143-09-EP | May 2009 | January 2010 | April 6, 2009 | January 12, 2010 |
|
||||
19 | NCT00209755 | Terminated | Plasma Ribavirin Assay During Combination Therapy for Chronic Hepatitis C |
|
|
Interventional | Not Applicable |
|
Other |
|
|
40 | All | 18 Years to 65 Years (Adult) | NCT00209755 | ribatop - afssaps #031161 N.A. |
October 2003 | July 2004 | September 21, 2005 | September 21, 2005 |
|
|||
20 | NCT00724776 | Completed | Albinterferon Alfa 2b Single Dose in Japanese Chronic Hepatitis C Patients |
|
|
Interventional | Phase 1 |
|
Industry |
|
|
30 | All | 20 Years to 69 Years (Adult, Senior) | NCT00724776 | CABF656A1202 | July 2008 | July 2009 | July 30, 2008 | August 11, 2010 |
|
|||
21 | NCT03429439 | Recruiting | Study on Effect of Intestinal Microbiota Transplantation in Chronic Hepatitis B |
|
|
Interventional | Not Applicable |
|
Other |
|
|
60 | All | 18 Years to 65 Years (Adult) | NCT03429439 | 2017003 | CHB | December 29, 2017 | October 2020 | November 2020 | February 12, 2018 | February 12, 2018 |
|
|
22 | NCT03481036 | Recruiting New |
DAA Therapy in Pediatric Patients With Chronic Hepatitis C |
|
|
Interventional | Not Applicable |
|
Other |
|
|
100 | All | 12 Years to 18 Years (Child, Adult) | NCT03481036 | IEC/2018/000323 | June 18, 2016 | December 31, 2020 | December 31, 2020 | March 29, 2018 | March 29, 2018 |
|
||
23 | NCT00200343 | Completed Has Results |
Efficacy and Safety Study of Ursodeoxycholic Acid to Treat Chronic Hepatitis C |
|
|
Interventional | Phase 3 |
|
Industry |
|
|
596 | All | 20 Years and older (Adult, Senior) | NCT00200343 | MT711-01 | July 2002 | December 2004 | September 20, 2005 | March 12, 2012 | November 7, 2011 |
|
||
24 | NCT02452528 | Terminated Has Results |
Study of ARC-520 in Participants With Hepatitis B Virus e Antigen (HBeAg) Positive Chronic Hepatitis B Virus |
|
|
Interventional | Phase 2 |
|
Industry |
|
|
4 | All | 18 Years to 75 Years (Adult, Senior) | NCT02452528 | Heparc-2004 | August 2015 | December 2016 | December 2016 | May 22, 2015 | December 5, 2017 | November 1, 2017 |
|
|
25 | NCT00763568 | Completed | 4-Week Lead-In With Nitazoxanide Followed by 36 Weeks Nitazoxanide and Peginterferon Alfa-2a in Chronic Hepatitis C |
|
|
Interventional | Phase 2 |
|
Industry |
|
|
40 | All | 18 Years and older (Adult, Senior) | NCT00763568 | RM01-3037 | August 2006 | September 2008 | September 2008 | October 1, 2008 | October 1, 2008 |
|
||
26 | NCT02862106 | Completed Has Results |
Second Stage:Open-label Study of Therapeutic Hepatitis B Vaccine (Mimogen-based) for Chronic Hepatitis B |
|
|
Interventional | Phase 2 |
|
Industry / Other |
|
|
209 | All | 18 Years to 65 Years (Adult) | NCT02862106 | 71006.01-2 | September 2010 | March 2013 | March 2013 | August 10, 2016 | March 31, 2017 | January 18, 2017 |
|
|
27 | NCT00291616 | Completed | Efficacy Study of Thymosin alpha1 & Pegylated Interferon-alpha2a to Treat Chronic Hepatitis B |
|
|
Interventional | Phase 4 |
|
Other / Industry |
|
|
52 | All | 18 Years and older (Adult, Senior) | NCT00291616 | 12-05-008 | December 2005 | August 2008 | August 2008 | February 14, 2006 | July 21, 2011 |
|
||
28 | NCT01760122 | Completed | Efficacy and Safety of Peginterferon Alfa-2b in HBeAg Positive Chronic Hepatitis B |
|
|
Interventional | Phase 3 |
|
Industry / Other |
|
|
820 | All | 18 Years to 65 Years (Adult) | NCT01760122 | TB1211IFN | March 2013 | July 2015 | August 2015 | January 3, 2013 | August 31, 2015 |
|
||
29 | NCT01655966 | Unknown † | Vitamin D as an add-on Therapy With Pegylated Interferon and Ribavirin for Chronic Hepatitis c |
|
|
Interventional | Phase 3 |
|
Other |
|
|
80 | All | 18 Years to 65 Years (Adult) | NCT01655966 | RAIL002 | May 2012 | February 2014 | April 2014 | August 2, 2012 | January 29, 2014 |
|
||
30 | NCT02973646 | Recruiting | Peginterferon Alfa-2b Treatment in HBeAg(+) Chronic Hepatitis b Patients Based on Interferon Gene Mutation and Receptor Detection |
|
|
Interventional | Phase 4 |
|
Other |
|
|
100 | All | 18 Years to 65 Years (Adult) | NCT02973646 | PL2 | January 2016 | December 2018 | December 2018 | November 25, 2016 | November 25, 2016 |
|
||
31 | NCT01726946 | Completed | A Phase 2 Study to Evaluate the Safety and Efficacy of VX-135 With Ribavirin in Treatment-Naïve Subjects With Chronic Hepatitis C |
|
|
Interventional | Phase 2 |
|
Industry |
|
|
10 | All | 18 Years to 60 Years (Adult) | NCT01726946 | VX12-135-101 | November 2012 | February 2014 | February 2014 | November 15, 2012 | April 16, 2015 |
|
||
32 | NCT00715715 | Withdrawn | Efficacy Study of Prednisone Priming to Treat Asian Chronic Hepatitis B Patients |
|
|
Interventional | Not Applicable |
|
Other |
|
|
0 | All | 16 Years and older (Child, Adult, Senior) | NCT00715715 | 08-01-IVA6 | April 2008 | February 2011 | February 2011 | July 15, 2008 | April 20, 2012 |
|
||
33 | NCT01769833 | Unknown † | HBsAg Decline After Pegylated-interferon-α in e Antigen Positive Chronic Hepatitis B With Nucleoside Maintenance |
|
|
Interventional | Phase 3 |
|
Other |
|
|
144 | All | 18 Years and older (Adult, Senior) | NCT01769833 | ML25659 | May 2013 | May 2015 | May 2016 | January 17, 2013 | November 4, 2014 |
|
||
34 | NCT01684787 | Completed | Study to Evaluate the Treatment for Chronic Hepatitis C With Normal Transaminases in HIV Positive Patients |
|
|
Interventional | Phase 4 |
|
Other |
|
|
80 | All | 18 Years to 70 Years (Adult, Senior) | NCT01684787 | Miguel Santín | CONTRA | September 2006 | May 2011 | June 2011 | September 13, 2012 | September 13, 2012 |
|
|
35 | NCT02387684 | Recruiting | Efficay of Extended Peginterferon Alpha 2a Treatment in HBeAg Negative Chronic Hepatitis B Patients |
|
Observational |
|
Other |
|
|
120 | All | 18 Years to 60 Years (Adult) | NCT02387684 | DTXY007 | April 2012 | December 2016 | December 2016 | March 13, 2015 | August 19, 2016 |
|
||||
36 | NCT01531166 | Completed | A Cohort Study in Korean Patients With Chronic Hepatitis B (CHB) Receiving Pegylated Interferon |
|
|
Observational |
|
Other |
|
|
500 | All | 20 Years to 65 Years (Adult) | NCT01531166 | 4-2011-0461 | September 2011 | August 2014 | October 2014 | February 10, 2012 | August 17, 2016 |
|
|||
37 | NCT03357822 | Not yet recruiting | A Real-World Study of Pegylated Interferon In Nucleoside-treated Patients With Chronic Hepatitis B |
|
|
Interventional | Phase 4 |
|
Other |
|
|
2000 | All | 18 Years to 65 Years (Adult) | NCT03357822 | COST study | COST | January 1, 2018 | October 1, 2020 | October 1, 2021 | November 30, 2017 | November 30, 2017 |
|
|
38 | NCT02362490 | Recruiting | Efficacy of Peginterferon Alpha 2a Therapy in Chronic Hepatitis B Patients Being Treated With Nucleoside(Acid) Analogues |
|
|
Interventional | Phase 4 |
|
Other |
|
|
200 | All | 18 Years to 60 Years (Adult) | NCT02362490 | DTXY004 | January 2013 | December 2016 | December 2016 | February 13, 2015 | September 13, 2016 |
|
||
39 | NCT02851069 | Active, not recruiting | Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C in Colombia |
|
Observational |
|
Industry |
|
|
66 | All | 18 Years to 99 Years (Adult, Senior) | NCT02851069 | P16-024 | outCome | February 27, 2017 | June 30, 2018 | June 30, 2018 | August 1, 2016 | January 17, 2018 |
|
|||
40 | NCT01522625 | Active, not recruiting | Tenofovir in Chronic Hepatitis B With Mild ALT Elevation |
|
|
Interventional | Phase 4 |
|
Other / Industry |
|
|
160 | All | 25 Years to 70 Years (Adult, Senior) | NCT01522625 | EMRP36100N | January 2012 | January 2018 | December 2018 | January 31, 2012 | March 21, 2017 |
|
||
41 | NCT01326546 | Unknown † | Therapeutic Hepatitis B Vaccine (Synthesized Peptide εPA-44) Joint Entecavir in Treating Chronic Hepatitis B Patients |
|
|
Interventional | Phase 2 |
|
Industry / Other |
|
|
378 | All | 18 Years to 65 Years (Adult) | NCT01326546 | 71006.04 | THBVJEITCHBP | June 2010 | December 2012 | March 2013 | March 31, 2011 | June 13, 2012 |
|
|
42 | NCT01887275 | Completed | A Control Study to Evaluate The Efficacy And Safety of Ozone-therapy in Chronic Hepatitis B |
|
|
Interventional | Phase 4 |
|
Other |
|
|
439 | All | 12 Years to 60 Years (Child, Adult) | NCT01887275 | gyb61641947 | March 2010 | February 2013 | February 2013 | June 26, 2013 | June 26, 2013 |
|
||
43 | NCT01189656 | Unknown † | A Clinical Study on Therapeutic Double-plasmid Hepatitis B Virus (HBV) DNA Vaccine in Patients With HBeAg-positive Chronic Hepatitis B |
|
|
Interventional | Phase 2 |
|
Other |
|
|
33 | All | 18 Years to 65 Years (Adult) | NCT01189656 | 71007.02 | January 2009 | November 2010 | December 2010 | August 27, 2010 | August 27, 2010 |
|
||
44 | NCT02143180 | Unknown † | Accuracy of RTE for Evaluating Hepatic Fibrosis in Chronic Hepatitis: a Prospective Multicenter Study |
|
Observational |
|
Other |
|
|
500 | All | 5 Years to 70 Years (Child, Adult, Senior) | NCT02143180 | ThirdSunYatSen | May 2014 | December 2015 | May 20, 2014 | May 20, 2014 |
|
|||||
45 | NCT00830609 | Completed | High Dose Versus Standard Dose of Ribavirin in Patients With Chronic Hepatitis C, Genotype 3 |
|
|
Interventional | Phase 4 |
|
Other |
|
|
101 | All | 18 Years to 70 Years (Adult, Senior) | NCT00830609 | ROCHE FARMA S.A. | DARGEN-3 | November 2008 | September 2011 | December 2011 | January 28, 2009 | March 13, 2012 |
|
|
46 | NCT02725866 | Completed | Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Participants With Chronic Hepatitis C |
|
Observational |
|
Industry |
|
|
216 | All | 18 Years to 99 Years (Adult, Senior) | NCT02725866 | P15-842 | April 5, 2016 | October 20, 2017 | October 20, 2017 | April 1, 2016 | October 24, 2017 |
|
||||
47 | NCT02798315 | Completed | Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study |
|
Observational |
|
Industry |
|
|
40 | All | 18 Years to 99 Years (Adult, Senior) | NCT02798315 | P15-699 | May 25, 2016 | June 12, 2017 | June 12, 2017 | June 14, 2016 | June 21, 2017 |
|
||||
48 | NCT02387463 | Completed | Efficacy of Extended Peginterferon Alpha 2a Treatment in HBeAg Positive Chronic Hepatitis B Patients |
|
Observational |
|
Other |
|
|
160 | All | 18 Years to 60 Years (Adult) | NCT02387463 | DTXY008 | March 2012 | May 21, 2017 | May 21, 2017 | March 13, 2015 | July 6, 2017 |
|
||||
49 | NCT01533051 | Unknown † | Prospective Observational Cohort Study for the Durability of Anti-viral Therapy in Patients With Chronic Hepatitis B |
|
Observational |
|
Other |
|
|
100 | All | 20 Years to 75 Years (Adult, Senior) | NCT01533051 | Quit Anti-viral therapy | February 2012 | March 2015 | March 2016 | February 15, 2012 | May 8, 2012 |
|
||||
50 | NCT02817594 | Active, not recruiting | Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin and Patient Support Program in Patients With Chronic Hepatitis C (3DUTCH) |
|
Observational |
|
Industry |
|
|
52 | All | 18 Years to 99 Years (Adult, Senior) | NCT02817594 | P15-788 | 3DUTCH | January 25, 2016 | September 1, 2018 | September 1, 2018 | June 29, 2016 | February 5, 2018 |
|
† Study has passed its completion date and status has not been verified in more than two years.